Jefferies Group reissued their buy rating on shares of GlaxoSmithKline PLC (NYSE:GSK) in a research note issued to investors on Wednesday morning.

Other equities analysts have also recently issued research reports about the company. BNP Paribas restated a neutral rating on shares of GlaxoSmithKline PLC in a report on Sunday, July 31st. Beaufort Securities restated a buy rating on shares of GlaxoSmithKline PLC in a report on Friday, June 3rd. Cowen and Company cut GlaxoSmithKline PLC from an outperform rating to a market perform rating in a report on Thursday, May 26th. Shore Capital restated a hold rating on shares of GlaxoSmithKline PLC in a report on Wednesday, July 27th. Finally, Zacks Investment Research upgraded GlaxoSmithKline PLC from a hold rating to a buy rating and set a $46.00 price target for the company in a report on Tuesday, June 21st. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $47.19.

GlaxoSmithKline PLC (NYSE:GSK) opened at 43.30 on Wednesday. The firm has a market capitalization of $105.24 billion, a PE ratio of 2706.25 and a beta of 0.85. The stock has a 50 day moving average of $43.97 and a 200-day moving average of $42.57. GlaxoSmithKline PLC has a one year low of $37.24 and a one year high of $45.58.

The business also recently announced a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Friday, August 12th will be given a $0.494 dividend. The ex-dividend date of this dividend is Wednesday, August 10th. GlaxoSmithKline PLC’s dividend payout ratio is presently 6,600.00%.

A number of large investors have recently modified their holdings of GSK. Williams Jones & Associates LLC raised its stake in shares of GlaxoSmithKline PLC by 176.1% in the second quarter. Williams Jones & Associates LLC now owns 10,975 shares of the pharmaceutical company’s stock valued at $476,000 after buying an additional 7,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of GlaxoSmithKline PLC by 8.7% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 131,171 shares of the pharmaceutical company’s stock valued at $5,684,000 after buying an additional 10,484 shares in the last quarter. Lincluden Management Ltd. raised its stake in shares of GlaxoSmithKline PLC by 11.1% in the second quarter. Lincluden Management Ltd. now owns 120,116 shares of the pharmaceutical company’s stock valued at $5,206,000 after buying an additional 12,041 shares in the last quarter. IFP Advisors Inc raised its stake in shares of GlaxoSmithKline PLC by 15.8% in the second quarter. IFP Advisors Inc now owns 31,542 shares of the pharmaceutical company’s stock valued at $1,367,000 after buying an additional 4,301 shares in the last quarter. Finally, Sterling Capital Management LLC raised its stake in shares of GlaxoSmithKline PLC by 13.3% in the second quarter. Sterling Capital Management LLC now owns 9,319 shares of the pharmaceutical company’s stock valued at $404,000 after buying an additional 1,091 shares in the last quarter. 9.03% of the stock is currently owned by hedge funds and other institutional investors.

About GlaxoSmithKline PLC

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

5 Day Chart for NYSE:GSK

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.